A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces ...

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and ...

U.S. Health and Human Services Secretary Robert Kennedy made his first appearance May 14 before the Senate Health, Education, ...

Small interfering RNA (siRNA) gained another vote of confidence, albeit back end-loaded, from big pharma as privately held ...

The metabotropic nucleotide receptor P2Y14 shows strong potential as a therapeutic target against various inflammatory ...

Mirvie Inc. continues the development of precision medicine for pregnancy-related conditions with its Encompass blood test to ...

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing ...

Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the ...

Aberrant activation of β-catenin, often due to mutations in its encoding gene or loss-of-function mutations in APC, contributes to tumor progression and therapy resistance, as seen in advanced ...

Researchers from Protagonist Therapeutics Inc. reported the preclinical characterization of PN-881, an oral macrocyclic peptide that inhibits the dimeric forms of IL-17 – AA, AF, and FF.